NAS:AQB (USA) Also trade in: Germany UK USA

AquaBounty Technologies Inc

$ 3 -0.05 (-1.64%)
Volume: 196,715 Avg Vol (1m): 239,411
Market Cap $: 64.80 Mil Enterprise Value $: 61.19 Mil
P/E (TTM): 0.00 P/B: 1.65
Earnings Power Value -5.99
Net Current Asset Value 0.21
Tangible Book 1.76
Projected FCF -4.13
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.90
Cash-To-Debt ranked lower than
78.39% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
AQB: 1.9
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.16, Med: 1.52, Max: 10000
Current: 1.9
0.16
10000
Equity-to-Asset 0.83
Equity-to-Asset ranked higher than
76.80% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
AQB: 0.83
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.83, Med: 0.84, Max: 0.85
Current: 0.83
0.83
0.85
Debt-to-Equity 0.15
Debt-to-Equity ranked higher than
68.80% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
AQB: 0.15
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -36.96, Med: 0.16, Max: 3.18
Current: 0.15
-36.96
3.18
Debt-to-EBITDA -0.42
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
AQB: -0.42
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.73, Med: -0.36, Max: -0.28
Current: -0.42
-0.73
-0.28
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.78
DISTRESS
GREY
SAFE
Beneish M-Score -1.44
Not Manipulator
Manipulator

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -6511.59
Operating Margin ranked lower than
94.70% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
AQB: -6511.59
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -17418.87, Med: -14807.08, Max: -6511.59
Current: -6511.59
-17418.87
-6511.59
Net Margin % -6521.95
Net Margin ranked lower than
94.57% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
AQB: -6521.95
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -17469.81, Med: -14841.97, Max: -6521.95
Current: -6521.95
-17469.81
-6521.95
ROE % -43.57
ROE ranked lower than
52.28% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
AQB: -43.57
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -1106.52, Med: -127.24, Max: -43.57
Current: -43.57
-1106.52
-43.57
ROA % -36.51
ROA ranked lower than
52.95% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
AQB: -36.51
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -203, Med: -102.28, Max: -36.51
Current: -36.51
-203
-36.51
ROC (Joel Greenblatt) % -44.87
ROC (Joel Greenblatt) ranked higher than
69.98% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
AQB: -44.87
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -849.79, Med: -387.26, Max: -44.87
Current: -44.87
-849.79
-44.87
3-Year Total EBITDA Growth Rate -11.20
3-Year EBITDA Growth Rate ranked lower than
60.97% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
AQB: -9.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -9.3, Med: 13, Max: 34.6
Current: -9.3
-9.3
34.6
3-Year EPS w/o NRI Growth Rate -100.00
3-Year EPS w/o NRI Growth Rate ranked lower than
96.33% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
AQB: -100
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -100, Med: 10.6, Max: 39.9
Current: -100
-100
39.9

» AQB's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:AQB

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 541714    SIC : 8731
Compare NAS:PLXP NAS:VBLT OHEL:BIOBV XPAR:SIGHT TSE:6090 NAS:AZRX OSTO:MVIR B ROCO:4171 NAS:CLSD OSTO:ACTI OSTO:ACE XPAR:ONXEO XKRX:138610 OTCPK:IGXT AMEX:ATNM NAS:INNT NAS:FWP XTAE:EVGN TSE:4575 TSX:PMN
Traded in other countries W8NB.Germany ABTX.UK AQBT.USA
Address Two Mill and Main Place, Suite 395, Maynard, MA, USA, MA 01754
AquaBounty Technologies Inc is a biotechnology company. It is engaged in research, development, and commercialization of the commercial viability of a group of proteins, antifreeze proteins. The company primarily focuses on the managing aquaculture productivity. Its lead product is the AquAdvantage Salmon, a genetically modified animal for human consumption. Geographically, all the operation of the group is functioned through the region of US and it derives revenue from the sale of AquAdvantage Salmon.

Ratios

Current vs industry vs history
PB Ratio 1.65
PB Ratio ranked higher than
76.20% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
AQB: 1.65
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 25.26
Current: 1.65
0
25.26
EV-to-EBIT -3.92
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
AQB: -3.92
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -10.53, Med: 0, Max: 0
Current: -3.92
-10.53
0
EV-to-EBITDA -4.39
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
AQB: -4.39
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -10.76, Med: 0, Max: 0
Current: -4.39
-10.76
0
EV-to-Revenue 256.91
EV-to-Revenue ranked lower than
93.00% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
AQB: 256.91
Ranked among companies with meaningful EV-to-Revenue only.
N/A
Current Ratio 7.24
Current Ratio ranked lower than
61.27% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
AQB: 7.24
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.51, Med: 3.83, Max: 32.31
Current: 7.24
0.51
32.31
Quick Ratio 7.10
Quick Ratio ranked lower than
58.66% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
AQB: 7.1
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.45, Med: 3.75, Max: 32.18
Current: 7.1
0.45
32.18
Days Inventory 261.08
Days Inventory ranked lower than
96.26% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
AQB: 261.08
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 261.08, Med: 597.88, Max: 615.49
Current: 261.08
261.08
615.49
Days Payable 707.19
Days Payable ranked lower than
92.35% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
AQB: 707.19
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 707.19, Med: 4759.18, Max: 7800.98
Current: 707.19
707.19
7800.98

Dividend & Buy Back

Current vs industry vs history

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.70
Price-to-Tangible-Book ranked higher than
81.66% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
AQB: 1.7
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.7, Med: 15.16, Max: 16.67
Current: 1.7
1.7
16.67
Earnings Yield (Joel Greenblatt) % -25.31
Earnings Yield (Greenblatt) ranked lower than
72.62% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
AQB: -25.31
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -32.64, Med: 0, Max: 0
Current: -25.31
-32.64
0

More Statistics

Revenue (TTM) (Mil) $ 0.16
EPS (TTM) $ -0.91
Beta 0
Volatility % 36.27
52-Week Range $ 1.51 - 5.45
Shares Outstanding (Mil) 15.1

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y